

REMARKS

This paper is filed in response to the Office Action mailed August 11, 2008. Applicants acknowledge with appreciation the indication that claims 1, 5-9, 16, 17, 22-25, and 33-36 are allowed and claims 5, 13-16, 29, and 33-36 have been rejoined. Applicants note that claims 13-15 and 29 are rejected. The amendments to the claims correct typographical errors and do not add new matter. Furthermore, claims 2-4, 10-12, 18-21, 26-28, and 30-32 have been canceled without prejudice or disclaimer. Entry of this Amendment is respectfully requested.

OBJECTION

Claim 15 is objected to because of minor typographical errors. Applicants have amended the claim to recite “administering a therapeutic amount” and to delete the last reference to “in need thereof.” Applicants respectfully submit that these amendments obviate these objections and request withdrawal thereof.

35 USC 112, SECOND PARAGRAPH

Claims 13-15 and 29 are rejected under 35 USC 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter, which Applicants regard as the invention.

Claims 13 and 29 are rejected for the recitation of “suitable bola amphiphile.” Applicants have amended claims 13 and 29 to provide proper antecedent basis to the earlier-disclosed triblock bola amphiphiles.

Claim 14 is rejected as reciting a method of encapsulating a “therapeutic treatment.” Applicants have amended the claim to recite a method of encapsulating a therapeutic agent.

Claim 15 is rejected because it is allegedly unclear as to what is meant by an “effective” amount. Applicants have amended the claim to recite a therapeutic amount.

Applicants believe that the above-amendments obviate the instant rejections under 35 USC 112, second paragraph. Withdrawal of the rejections is respectfully requested.

CONCLUSION

In conclusion, Applicants believe that these amendments overcome the outstanding rejections. Applicants, however, invite the Examiner to call the undersigned to discuss any remaining issues to expedite the prosecution of this application. The Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 50-4582.

Respectfully submitted,

NANOTOPE INC.

/Maria L. Maebius/

Maria L. Maebius
Registration No. 42,967

c/o Intellevate
P.O. Box 52050
Minneapolis, MN 55402
Tel. 202.253.7199
Fax 612-677-3572
Date: 10 November 2008